At present, there is insufficient evidence to recommend risk-reducing ovarian surgery in the carriers of PALB2 variants, but, in the absence of a proven benefit of ovarian cancer screening, it could be considered in the post-menopausal setting, after non-directive counselling. The gene discussed is PALB2; the disease is ovarian cancer.